Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
1995-02-23
2008-07-22
Crouch, Deborah (Department: 1632)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C435S320100
Reexamination Certificate
active
07402308
ABSTRACT:
The invention provides a method of delivering a selected DNA sequence to the central nervous system of a mammal by administering to said mammal a neurotropic virus, said virus containing a selected DNA sequence under the control of a promoter which permits expression of the DNA during the latent infectious state of the virus.
REFERENCES:
patent: 5849572 (1998-12-01), Glorioso
Nishimura et al (1986) Proced. Natl. Acad. Sci. 83, 7292-7296.
Fink et al. Advances in the Developmental of Herpes Simplex Virus-Based Gene Transfer Vectors of the Nervous System. Clinical Neuroscience. vol. 3, 1996, pp. 284-291.
Blomer et al. Applications of Gene Therapy to the CNS. Human Molecular Genetics. vol. 5 Review, 1996, pp. 1397-1404.
Eck et al. Gene Based Therapy in The Pharmacological Basis of Therapeutics, Goodman and Gillman, eds. 9thedition, McGraw-Hill New York, 1996, 77-101.
Wolfe et al. Herpesvirus Vector Gene Transfer and Expression of B-Glucuronidase in the Central Nervous System of MPS VII Mice. Nature Genetics. vol. 1, Aug. 1992, pp. 379-384.
Palella et al. Expression of Human HPRT mRNA in Brains of Mice Infected with a Recombinant Herpes Simplex Virus-1 Vector. Gene, vol. 80, 1989, pp. 137-144.
Dobson et al. Identification of the Latency-Associated Transcript Promoter by Expression of Rabbit Beta-Globin mRNA in Mouse Sensory Nerve Ganglia Latently Infected with a Recombinant Herpes Simplex Virus. J. Virology, vol. 63, 1989, pp. 3844-3851.
Nishimura et al. Nucleotide Sequence of Rat Preputial Glan B-Glucuronidase cDNA and In Vitro Insertion of its Encoded Polypeptide into Microsomal Membranes. Proced. Natl. Acad. Sci. USA, vol. 83, Oct. 1986, pp. 7292-7296.
Blau et al. Molecular Medicine: Gene Therapy—A Novel From of Drug Delivery, The New England Journal of Medicine. Nov. 2, 1995, pp. 1204-1207.
Verma et al. Gene Therapy—Promises, Problems and Prospects. Nature, vol. 389, Sep. 18, 1997, pp. 239-242.
Gene Therapy's Growing Pains. Science. vol. 269, Aug. 25, 1995, pp. 1050-1055.
Anderson. Gene Therapy. Scientific American. Sep. 1995, pp. 124-126 and 128.
Guise et al. Isolation and Expression inEscherichia coliof a cDNA Clone Encoding Human Beta-Glucuronidase. Gene. 1985, vol. 34, pp. 1-5-110.
Steiner et al., “A herpes simplex virus type 1 mutant containing a non-transinducing Vmw65 protein establishes latent infection in mouse trigeminal ganglia in the absence of viral replication”,J Virol, 64:1630-1638 (1990).
Steiner et al., “Herpes simplex virus type 1 latency-associated transcripts are not essential for latent infection,” EMBO 8:505-511 (1989).
Stevens et al., “RNA complementary to a herpesvirus a gene mRNA is prominent in latently infected neurons,” Science 235:1056-1969 (1987).
Tenser, et al., “Latency-associated transcript but not reactivatable virus is present in sensory ganglion neurons after inoculation of thymidine kinase-negative mutants of herpes simplex virus type 1,” J. Virol. 63:2861-2865 (1989).
Ugolini et al., “Transneuronal transfer of herpes virus from peripheral nerves to cortex and brainstem”,Science243:89-91 (1989).
Villarreal et al., “Hybridization in situ of SV40 plaques: detection of recombinant SV40 virus carrying specific sequences of nonviral DNA,” Science 196:183-185 (1977).
Vogler et al., “A murine model of mucopolysaccharidosis VII. Gross and microscopic findings in beta-glucuronidase-deficient mice”, Am. J. Pathol., 136:207-217 (1990).
Wechsler et al., J Virol. 62:4051-58 (1988).
Wolfe, et al., “Restoration of normal lysosomal function in mucopolysaccharidosis type VII cells by retroviral vector-mediated gene transfer,” Proc. Natl. Acad. Sci. 87:2877-2881 (1990).
Card et al., “Neurotropic properties of pseudorables virus: uptake and transneuronal passage in the rat central nervous system”,J. Neurosci., 10:1974-1994 (1990).
Deiss et al., “The herpes simplex amplicon: cleavage of concatemeric DNA is linked to packaging and involves the amplification of the terminally reiterated a sequence,”J. Virol.57:933-941 (1986).
Dobson et al., “Identification of the latency-associated transcript promoter by expression of rabbit β-globin mRNA in mouse sensory nerve ganglia latently infected with a recombinant herpes simplex virus”, J Virology, vol. 63, No. 9, pp. 3844-3851 (1989).
Fraser et al., “Molecular biology of latent HSV-1, In: Human herpes virus infections. II viral glycoproteins and immunobiology”, Raven Press NY 39-55 (1986).
Friedmann, T., “Progress toward human gene therapy”,Science244:1275-1281 (1989).
Geller, A.I., Breakfield, X.O., “A defective HSV-1 vector expressesEscherichia coliβ-galactosidase in cultured peripheral neurons”, Science, 241:1667-69 (Sep. 23, 1988).
Geller, A.I., Freese, A., “Infection of cultured central nervous system neurons with a defective herpes simplex virus 1 vector results in stable expression ofEscherichia coliβ-galactosidase”, Proc Natl Acad Sci, 87:1149-1153 (1990).
Goldstein et al., “An ICP6::lacZ insertion mutagen is used to demonstrate that the UL52 gene of herpes simplex virus type 1 is required for virus growth and DNA synthesis,” J. Virol. 62:2970-2977 (1988).
Ho et al., “β-galactosidase as a marker in the peripheral and neural tissues of the herpes simplex virus-infected mouse,” Virology 167: 279-283 (1988).
Ho et al., “Herpes simplex virus latent RNA (LAT) is not required for latent infection in the mouse,” Proc. Natl. Acad. Sci. USA 86:7596-7600.
Hoogerbrugge et al., “Donor-derived cells in the central nervous system of twitcher mice after bone marrow transplantation”,Science239:1035-1038 (1988).
Leib et al., “A deletion mutant of the latency-associated transcript of herpes simplex virus type 1 reactivates from the latent state with reduced frequency,” J. Virol. 63:2893-2900 (1989).
McGeoch et al., Gen Virol, 69:1531-4 (1988).
Pallela et al., “Expression of human HPRT in mRNA in brains of mice infected with a recombinant herpes simplex virus-1 vector”,Gene, 80:137-44 (1989).
Pallela et al., “Herpes simplex virus-mediated human hypoxanthine-guanine phosphoribosyltransferase gene transfer into neuronal cells”, Molecular and Cellular Biology, vol. 8, No. 1 pp. 457-460 (1988).
Perry et al., J Gen Virol. 69:2931-46 (1988).
Spaete et al., “The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector,” Cell 30:295-304 (1982).
Spivack et al., “Detection of herpes simplex virus type 1 transcripts during a latent infection in mice,” J. Virol. 61:3841-3847 (1987).
Fraser Nigel W.
Wolfe John H.
Crouch Deborah
Licata & Tyrrell PC
The Wistar Institute
Trustees of the University of Pennsylvania
LandOfFree
Method of delivering genes to the central nervous system of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of delivering genes to the central nervous system of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of delivering genes to the central nervous system of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3970946